FDA Patent Listing Rule Changes “Likely” To Affect Polymorphs
Executive Summary
The proposal to allow "Orange Book" listing of polymorph patents is the area "most likely" to change in FDA's upcoming Waxman/Hatch final rule, attorney and former Deputy Commissioner William Schultz predicted